About the Company
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ACRS News
Aclaris Therapeutics: A Year of Financial Resilience and Steady Advancements
WAYNE, PA — Hailed as a leader in kinase discovery and development, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) began 2024 in a ...
Aclaris Therapeutics Inc ACRS
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks
Aclaris Therapeutics (ACRS) Company Description: Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing ...
Aclaris: Q4 Earnings Snapshot
WAYNE, Pa. (AP) — WAYNE, Pa. (AP) — Aclaris Therapeutics Inc. (ACRS) on Tuesday reported a loss of $1.5 million in its fourth quarter. The Wayne, Pennsylvania-based company said it had a loss ...
Aclaris Therapeutics Inc earnings beat by $0.33, revenue topped estimates
Investing.com - Aclaris Therapeutics Inc (NASDAQ: ACRS) reported fourth quarter EPS of $-0.02, $0.33 better than the analyst estimate of $-0.35. Revenue for the quarter came in at $17.57M versus the ...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno ...
Aclaris Therapeutics Inc ACRS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Aclaris Therapeutics Inc
Analysts say investors should buy these undervalued stocks.
Aclaris Therapeutics Inc (ACRS)
Investing.com - Aclaris Therapeutics Inc (NASDAQ: ACRS) reported third quarter EPS of $-0.41, $0.07 better than the analyst estimate of $-0.48. Revenue for the quarter came in at ...
Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates ...
Loading the latest forecasts...